© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Turning back to the 1950s, researchers started to dig deep into how cells generate power. The tale of oligomycin starts with soil samples from the earth, a reminder that discoveries often spring from the most unassuming places. Streptomyces, a genus of bacteria, handed scientists a new antibiotic—oligomycin—through careful extraction and purification processes. At the time, scientists viewed antibiotics mainly as frontline tools against infections, but oligomycin’s biggest impact emerged not as a treatment, but as a research tool.
Oligomycin doesn’t neatly fit into everyday medicine cabinets. This compound, categorized as a macrolide antibiotic, stands out for its complex ring structure with alternating oxygen and carbon atoms, compacting into a molecular formula of C45H74O11. Its most famous act lies in blocking ATP synthase within mitochondria. Anyone who has cracked open a biology textbook remembers the mitochondrion as the so-called powerhouse of the cell. Oligomycin makes that analogy tangible, flipping the “switch” off for ATP production. In a sense, it pulls the plug in the lab, revealing what goes wrong or what goes on when cells can’t generate ATP. This fact alone makes it a standard item in bioenergetics research and metabolic studies, allowing direct observation of mitochondrial function or dysfunction.
Oligomycin presents as a white to off-white amorphous solid, typically isolated as a mixture since several related oligomycin compounds exist, collectively called oligomycin A, B, C, and so on. These structural analogs share a core but show subtle differences that slightly modify their physical or chemical characteristics. The molecule’s relatively high molecular weight and cyclic structure lend a certain stability, but it remains light-sensitive and degrades under prolonged exposure to air or heat. As a substance that works at tiny concentrations in cell culture, its solubility in organic solvents like ethanol or DMSO is helpful for research.
Every bottle of oligomycin marching through a lab wears a careful label—usually highlighting purity (often 95 percent or higher), the precise form (often Oligomycin A), storage conditions, and recommended concentrations for typical experiments. As a synthetic or semi-synthetic compound, details about batch numbers or expiration become essential. These checkpoints speak less to bureaucracy and more to reproducibility. Research doesn't move forward without reliable materials, and oligomycin serves as a textbook example.
Large-scale production of oligomycin essentially reflects a classic fermentation approach. Soil-derived Streptomyces bacteria feed on organic substrates, slowly releasing oligomycin into the broth. The process draws upon years of know-how in antibiotic fermentation, followed by extraction with organic solvents. Isolation employs chromatographic techniques, gradually building purer fractions. The final product emerges after crystallization and rigorous testing, capturing a blend of science and hands-in-the-mud microbiology.
Over the years, researchers have taken oligomycin and pushed its boundaries. Through selective methylation, acetylation, or even partial hydrolysis, scientists explore how modifications influence biological activity. These changes expand the research toolkit. For example, tweaking the molecule can increase its specificity, alter toxicity, or produce labeled compounds for detailed tracing inside cells. This avenue not only helps clarify how the parent molecule works but sometimes opens new questions about mitochondrial biology.
In literature, oligomycin rarely comes alone—its name changes depending on the audience. Some call it Oligomycin A or Streptovaricin, emphasizing its bacterial origin or subtle differences in molecular form. Though the world may know it by many aliases, the scientific community keeps tabs with standardized names using CAS numbers or IUPAC designations. Anyone handling research publications will run into these variations, reflecting history as much as chemistry.
Oligomycin demands respect. Even though it isn’t a therapeutic drug for people, its potential to block a fundamental cell process puts it in the category of hazardous compounds. Lab protocols advise gloves, goggles, and careful waste disposal. Anyone who underestimates its power risks harming not just cell cultures, but themselves. Proper ventilation, storage away from direct light, and immediate cleanup of spills are routine not just to satisfy regulations but to keep work safe. The mental checklist goes: respect what you cannot see, remember what the molecule can do.
Oligomycin’s reach stretches far beyond initial antibiotic interest. In biochemistry, it’s the gold standard for probing ATP synthesis. Pharmaceutical labs studying metabolic disease models often turn to oligomycin to disrupt mitochondrial function and observe consequences in cultured cells or isolated tissue. Cancer researchers monitor how tumor cells bypass blocked energy production. Since the compound sharply interferes with mitochondrial oxidative phosphorylation, it provides real-life stress tests for mitochondrial health. Even agricultural science sometimes deploys oligomycin or its analogs to gauge plant cell metabolism under stress.
Modern research continues to wring new answers from oligomycin. With every new mitochondrial disease or novel metabolic syndrome uncovered, researchers circle back to this compound, using it to simulate failures or rescue functions through workaround drugs. Animal models receiving dose-limited oligomycin help illuminate just how fragile ATP production can be. Studies combining oligomycin with other mitochondrial inhibitors or genetic manipulation yield vital details about redundancy and vulnerability inside living cells. Each year's work layers new findings atop established knowledge, providing a bedrock for future therapies.
Oligomycin’s knack for stopping ATP synthesis doesn’t discriminate between test tubes and living tissue. Cellular toxicity reflects directly on its mode of action; as it paralyzes mitochondrial machinery, cells starve for energy and function collapses. Cancer cells or rapidly dividing tissues face a particularly acute response, a fact used strategically in certain experimental oncology models. Toxicity profiles rely heavily on dose, exposure length, and cell type, but the message is clear—mitochondrial poisons rarely show mercy, making safety protocols more than just window dressing. Every exposure study published brings a reminder that foundational research tools are never entirely benign.
Oligomycin’s role in research deepens with each advance in mitochondrial medicine. As new therapies aim to tweak cell energy production—whether for inherited mitochondrial disease or metabolic disorders—researchers run head-on into core questions that oligomycin helped raise. Its use as a control or reference point in energy assays remains essential, particularly as high-throughput screening and live-cell analysis become more common. At the same time, further chemical modification promises research-only analogs with improved safety or selective activity. It's hard to picture a world of mitochondrial research or drug development where oligomycin doesn't keep its spot on the bench, not just as a historical artifact, but as a working tool for the next generation.
Oligomycin doesn’t pop up in everyday conversations, but its impact stretches across biology labs and sometimes even clinical discussions. This substance works by blocking a part of the mitochondrial machinery—ATP synthase. Blocking that gate stops cells from making the energy molecule ATP. If you stretch your memory back to school, mitochondria power every cell, so disrupting ATP production shakes cell metabolism at its core.
Researchers lean on oligomycin to study how cells generate energy. By putting the brakes on ATP generation, they can see which processes depend on fresh cellular fuel. This trick proves useful in metabolic research, cancer studies, and work on degenerative diseases. You can watch how a cancer cell, zapped of its energy source, switches strategies or even dies off. Scientists use oligomycin to look for weaknesses in diseases that thrive on faulty or overactive energy use.
Disease doesn’t always play by textbook rules, and studying live cells has its limitations. Oligomycin slices through the noise by giving researchers a way to trigger energy stress consistently. In my time in the lab, I watched teams use it to mimic the energy crisis inside cells affected by muscle disorders or nerve conditions. This helped the group map out the limits of muscle performance or how neurons react as their power flickers. Without oligomycin, tracking the domino cascade after energy failure wouldn’t hold nearly as much clarity.
Oligomycin’s talent for zapping ATP production finds a home in testing new drugs. Suppose a company wants to know if a molecule hurts healthy cells—they’ll often treat cells with oligomycin and their new compound together. If deterioration speeds up, the compound could cause mitochondrial stress. Using oligomycin speeds up the guesswork, keeping toxic substances out of the medicine pipeline sooner. As drug recalls keep making news, using tools to pinpoint mitochondrial risks early can’t be underestimated.
Oligomycin delivers strong punches to cell energy, so using it in actual patients would spell disaster—muscle failure, nerve breakdown, and more. Its value sits squarely in the research toolbox, not the medicine cabinet. Sometimes scientists get overzealous with it and stretch conclusions about disease that don’t all add up in real patients.
If science wants to bridge the gap between petri dish results and real-world treatments, oligomycin works best as a momentary wrench in the cell’s gears. Newer research calls for nuanced use—pairing oligomycin with other metabolic blockers or genetic tweaks to refine results. Transparency helps here. Journals and review boards expect scientists to spell out why they use this compound, and savvy readers look for these explanations.
My own research years saw oligomycin transform confusion into clarity: Whether poking at cardiac cells or probing deadly infections, watching what happens after the “energy shutoff” event gave me insights you can’t fake on paper. The world of metabolic diseases and cancer moves fast, but seeing energy unmasked by oligomycin continues to anchor some of the most eye-opening discoveries.
Every living cell relies on energy. ATP serves as the chief currency cells count on for nearly everything: chasing down nutrients, flexing a muscle, keeping nerves firing. The enzyme that manufactures this fuel — ATP synthase — brings together ADP and phosphate to crank out ATP, a job that takes place across the mitochondrial membrane. Without this energy flow, life grinds to a halt.
Oligomycin steps into this process like a wrench tossed into clockwork. Sourced from Streptomyces bacteria, this compound targets the F0 subunit of ATP synthase. The F0 section functions as the rotating motor that lets protons pass through the inner mitochondrial membrane. Each proton that zips through spins the turbine, making ATP creation possible.
Oligomycin fits itself right in that motor, blocking the channel. Protons line up at the gateway, unable to cross back into the mitochondrial matrix. Without the rush of protons passing through, the turbine doesn’t turn, bringing ATP production to a standstill. That means even if mitochondria pile up ADP and phosphate, ATP synthase can’t do its job. The result can get drastic; cells starve for energy almost immediately.
I’ve seen this play out in the biology lab. Add even a small dose of oligomycin, and cells curl up fast. No ATP means no protein construction, no maintenance, and, soon, no life. Mitochondria try to compensate, but the proton gradient reaches a dead end. The electron transport chain starts to back up since electrons hand off their energy to pump out protons. With nowhere to send protons, electrons can’t move. This doesn’t just slow energy production — it sends reactive oxygen species flying around, sparking stress responses and even cell death.
For researchers, oligomycin serves as a tool to prove that ATP really comes from oxidative phosphorylation. These experiments reveal just how connected each step inside mitochondria stays. Add oligomycin, metabolic readings crash, energy-hungry tissues in heart and muscle show quick symptoms. In some toxin exposure cases, you can actually trace the disruption to a shutdown of ATP synthase much like what oligomycin causes.
Blocking ATP synthase, intentionally or by accident, hurts fast-growing cells and energy-demanding organs. Muscle fatigue, heart failure, and certain degenerative diseases all show metabolic collapse when mitochondria stop working. There aren’t many safe ways to get around the problem. Sometimes, shifting to glycolysis can help cells keep going for a short while, but glycolysis just can’t keep up with mitochondrial ATP production, especially in organs like the brain and heart.
Better therapies aim to protect mitochondria or boost their repair. Some researchers screen for ways to bypass blocked ATP synthase, maybe by stimulating alternate energy-producing pathways or using antioxidants to calm down the cell. So far, success stays limited, but the drive to find mitochondria-safe drugs keeps growing, especially as more conditions trace back to energy shortfalls. Watching what oligomycin does in a dish has convinced generations of scientists just how brittle this system can be.
Researchers know Oligomycin as a tool for studying mitochondria. It blocks ATP synthase, shutting down energy production in cells. Lab teams count on Oligomycin to act as expected, but it won’t if the powder clumps or breaks down before experiments even start. I remember trying to troubleshoot poor cell viability in the lab, running around checking protocols and media. Turned out the compound drawer got too warm, and reagents like Oligomycin suffered for it. Problems like this waste time, eat up budgets, and leave everyone frustrated.
Oligomycin belongs with other sensitive antibiotics. It cannot handle heat, moisture, or light. Reliable storage calls for -20°C freezers, the kind meant for chemicals not food. I’ve seen bottles wrapped in foil to keep stray light out. Desiccant pouches live in the drawer, keeping the air dry. Once a vial comes out, researchers work fast to aliquot what they need and get it back to the cold, dark space as soon as possible.
Too high a temperature kicks off degradation. Even a night outside the freezer can turn trusted Oligomycin unreliable. Exposure to moisture ruins powder and liquid stocks alike. It cakes up, loses potency, or invites microbial growth. I once watched a postdoc dissolve Oligomycin in DMSO and then leave the bottle open, thinking a few hours on the bench made no difference. The results fell apart afterward. Mistakes like that stick with you and drive home the value of strict routines.
Reviews in journals like The Journal of Biological Chemistry describe Oligomycin’s instability above freezing. Product sheets from major suppliers such as Sigma-Aldrich or Thermo Fisher make these warnings clear: store at -20°C, shield from light, avoid water. Still, in high-traffic labs or clinics, rules are only followed as well as daily workflow and reminders allow. It takes solid habits, not just policies, to keep conditions right.
Everyone in a life sciences setting can share stories of mystery results traced back to poor chemical handling. Some labs put color stickers on vials to track how many times they left the freezer. Others use small aliquots, never opening a container more than they must. Good records matter, too. A sticker showing the last thaw date protects future users from ruined results.
Training helps plenty. New students must see mistakes up close to appreciate why the freezer routine exists. Writing a step-by-step protocol by the reagent shelf pays off, especially for less common compounds.
Technology has a place as well. Inventory software tracks storage times and temperatures. Alarms warn if a freezer climbs above target. Some labs go farther, logging every withdrawal and return, making sure expiry dates are not just suggestions.
Long story short: Oligomycin’s sensitivity calls for shared responsibility. Forgetting one time can spoil a week’s results and sink the work of many. By respecting storage guidelines and building good habits, research teams save resources and protect their science. That’s a principle I’ve seen hold up in every lab, whether in Boston, Bangalore, or Berlin.
Oligomycin turns up regularly in conversations among cell biologists. This compound, first isolated from Streptomyces bacteria, halts the mitochondrial ATP synthase dead in its tracks. It’s a powerful tool when the goal is measuring oxidative phosphorylation or studying how metabolism changes under stress.
Scientists routinely add oligomycin at concentrations between 1 to 2 μg/mL when treating mammalian cells. This range balances potency with cell viability. Go lower, the mitochondrial inhibition might be partial, missing the experimental mark. Go higher, and the cells will likely experience toxic effects beyond the intended ATP synthase shutdown.
In my graduate work, measuring mitochondrial respiration with a Seahorse Analyzer, I started with 1 μg/mL. Many commercial protocols recommend this starting point. Peer-reviewed studies from journals like Cell Reports and Nature Communications cite 1-2 μg/mL as the sweet spot for acute mitochondrial inhibition with consistency in both primary and immortalized cell lines.
Precision matters more than ever. A lot of public trust in biomedical research relies on figures reported in literature being reproducible from lab to lab. If the oligomycin concentration isn’t spot-on, downstream data like oxygen consumption rates get thrown off. Diverging from the standard range creates problems for anyone trying to repeat the experiment, whether that’s a fellow scientist or a regulatory body reviewing drug safety data.
Safety for researchers and cells alike also features heavily in my mind working around oligomycin. Anything that meddles with energy production in living cells can trigger sudden changes—cell death, metabolic shutdown, or even changes in gene expression. The published range keeps cells alive long enough to read out what matters, before off-target effects take over. For new cell lines or uncertain scenarios, a dose-response curve sheds light on where toxicity kicks in.
Measuring cell number and viability before and after oligomycin addition can flag concentrations that go too far. Colorimetric assays like MTT or trypan blue exclusion help guard against accidental over-dosing. Running vehicle-only controls, where ethanol or DMSO matches what’s in the oligomycin mixture, rules out side effects from the solvent instead of the inhibitor.
Consistently referring to published protocols and seeking input from experienced colleagues pays off. For instance, the Seahorse XF Cell Mito Stress Test, well-cited by the field, recommends exactly 1 μg/mL. Adjustments may be needed based on cell size or metabolic rate, but they come with transparency about what changed and why.
Wider adoption of open lab notebooks and sharing negative results speeds up the learning curve for everyone. If a specific batch of cells shows sensitivity outside the recommended range, reporting that result adds value. Documentation that tracks cell line, passage number, and batch keeps everything transparent for future work and regulatory review.
Relying on validated sources like peer-reviewed journals and manufacturer data sheets ensures the right concentration. Regularly updating protocols as new data rolls in protects data integrity in the long run.
Working in labs, you learn pretty quickly that even small quantities of certain substances can pack a punch. Oligomycin, a potent antibiotic mainly used as an inhibitor of ATP synthase in cell biology, falls squarely into that group. Once, while prepping some for a mitochondrial respiration experiment, I realized just how careful everyone needs to be—even around seemingly minor substances.
Oligomycin disrupts cellular energy production by shutting down ATP synthesis. That makes it a valuable research tool but also a clear hazard for human cells, not just those in the petri dish. Contact or inhalation can mess up your own mitochondrial activity in ways nobody wants to experience. Safety is not just recommended, it’s common sense.
Too many techs skip proper gear, figuring a little powder won’t hurt. It will. Nitrile gloves are a must because latex can degrade, and oligomycin can pass right through if you’re not careful. Adding a lab coat and certified eye protection keeps splashes from reaching your skin or eyes. I’ve seen a drop land on an uncovered wrist and cause a minor burn—luckily, it was caught early.
Masks matter here, especially with powders that float on the slightest draft. A standard disposable mask can cut down risk, but a properly fitted N95 or similar takes safety up a notch.
Any experiment using oligomycin belongs inside a certified chemical fume hood. The first time I worked outside of one, I realized the room air stayed contaminated for much longer than I anticipated. The airflow system draws away fine particles, so you don’t end up breathing them day in and day out. Cleaning up after handling it should mean more than just wiping down with a damp paper towel—a fresh, disposable pad with 70% ethanol works best.
One spill taught me that protocol saves you from panic. If you knock over a tube, stop everything. Alert your coworkers right away and refer to your lab’s chemical spill kit. Have one on hand; using it is much safer than improvising. I always sweep up powder with disposable pads, then add the waste to a labeled hazardous bin—nobody pours oligomycin down the drain. Improper disposal means risking environmental harm or accidental exposure by unsuspecting maintenance staff.
Training forms the backbone of lab safety. Reading up on oligomycin’s MSDS can feel dull, but few things stick like real stories. Inexperienced students I’ve mentored never forget the day they see a seasoned researcher carefully double-bag contaminated tips or transfer every used tube directly to a biohazard box. This attention to detail builds a culture of respect for what these compounds can do—both under the microscope and out in the open.
A safe lab depends on more than rules—it takes vigilance and habits that get built over time. Signs and reminders help, but mentoring makes the biggest difference. Calling out shortcuts and reminding people to suit up, even if it slows things down, keeps everyone healthy. Sharing a story every so often about accidents encourages folks not to let safety slip. In every case I’ve seen, the labs with zero incidents put daily effort into these small things. Oligomycin deserves that level of respect—and so does the health of everyone working nearby.
| Names | |
| Preferred IUPAC name | (3R,6R,9S,12S,15R,18S,21R,22E,25R,28S,29R)-6,9,18,28-tetramethyl-3-[(2R,3R,4R,5S,6R)-4,5,6-trihydroxy-3-methoxyoxan-2-yl]oxy-12,15,21,25,29-pentakis(propan-2-yl)-1-oxacyclotriaconta-22,31-diene-2,5,8,11,14,17,20,24,27,30-decone |
| Other names |
Mortimycin Mold Tack Penleistin Oligomycins |
| Pronunciation | /ˌoʊlɪɡoʊˈmaɪsɪn/ |
| Identifiers | |
| CAS Number | 1404-19-9 |
| Beilstein Reference | 25383 |
| ChEBI | CHEBI:28259 |
| ChEMBL | CHEMBL464545 |
| ChemSpider | 14803 |
| DrugBank | DB04572 |
| ECHA InfoCard | 100.168.750 |
| EC Number | 1.14.99.1 |
| Gmelin Reference | 142486 |
| KEGG | C01754 |
| MeSH | D009839 |
| PubChem CID | 5284447 |
| RTECS number | SL8650000 |
| UNII | 7BQM6U610A |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C45H74O11 |
| Molar mass | 791.034 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.21 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.85 |
| Acidity (pKa) | 7.2 |
| Basicity (pKb) | 1.23 |
| Refractive index (nD) | 1.528 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.50 D |
| Thermochemistry | |
| Std enthalpy of combustion (ΔcH⦵298) | -15148.6 kJ/mol |
| Pharmacology | |
| ATC code | D06AX01 |
| Hazards | |
| Main hazards | Toxic if swallowed, inhaled, or in contact with skin; causes damage to organs; suspected of causing genetic defects. |
| GHS labelling | GHS05, GHS06, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Danger |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P261, P273, P280, P301+P312, P305+P351+P338 |
| NFPA 704 (fire diamond) | Health: 3, Flammability: 1, Instability: 0, Special: |
| Autoignition temperature | 340°C |
| Lethal dose or concentration | LD₅₀ (mouse, intraperitoneal): 1 mg/kg |
| LD50 (median dose) | LD50: 30 mg/kg (mouse, intraperitoneal) |
| NIOSH | WQ3850000 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 2 µg/ml |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Aurantin Rutamycin Oligomycin B Oligomycin C |
